Carrier
Blue Cross and Blue Shield of North Carolina
Requires anti-obesity drug coverage on your plan, 6 months of lifestyle change first, and 5% weight loss to renew Wegovy, Zepbound or Foundayo.
Blue Cross NC's anti-obesity policy makes the benefit a criterion: to get Wegovy, Zepbound, Foundayo or Saxenda approved, you must have anti-obesity medication coverage. If your formulary excludes the drug, a non-formulary exception is the route.
Then the clinical bar. A BMI of 30, or 27 with a weight-related condition; a BMI of 25 counts for people of South Asian, Southeast Asian or East Asian descent. Your doctor also has to show you couldn't lose about a pound a week over 6 months with diet and activity, unless a weight-related condition needs treatment now.
The first approval lasts 180 days. To renew for a year, you need to have lost and kept off at least 5% of your starting weight.
What changed in 2026?
The policy dated July 2026 removed the step requirement for Foundayo. Earlier in 2026 Blue Cross NC added Foundayo, Wegovy HD and the Wegovy tablet to the policy.
Does it cover Zepbound for sleep apnea?
Yes, as a separate path: moderate to severe sleep apnea, a BMI of 30 or more, a sleep test, and an apnea-hypopnea index of 15 or more at baseline.
Every claim above, with the document behind it
These are the policies we opened and the month we opened them. Each one carries its own policy number and effective date on its face, and those are printed here as the document shows them.
Initial criteria include "The patient has anti-obesity medication coverage benefits" and "For formularies that exclude (non-formulary) the requested medication, Non-formulary Exception Criteria applies."
Blue Cross NC, Utilization Management Policy: Anti-Obesity Agents, NC Standard (July 2026), effective July 2026 · source
BMI thresholds include "A diagnosis of obesity and a BMI ≥ 30 kg/m2", "A diagnosis of obesity and a BMI ≥ 25 kg/m2 and the patient is of South Asian, Southeast Asian, or East Asian descent", or "a documented BMI ≥ 27 kg/m2 with at least one weight-related comorbidity".
Blue Cross NC, Utilization Management Policy: Anti-Obesity Agents, NC Standard (July 2026), effective July 2026 · source
"The patient was unable to achieve acceptable weight loss through lifestyle modifications (defined as a 1lb per week weight loss through calorie restriction, increased activity, and behavioral modifications in a 6 month period)", unless a weight-related condition "warrants medication interventions immediately".
Blue Cross NC, Utilization Management Policy: Anti-Obesity Agents, NC Standard (July 2026), effective July 2026 · source
"Duration of Approval: 180 days (6 months)" for the first approval; continuation needs "The patient has achieved and maintained a weight loss of ≥ 5% from baseline (prior to the initiation of requested medication)", with "Duration of Approval: 365 days (1 year)".
Blue Cross NC, Utilization Management Policy: Anti-Obesity Agents, NC Standard (July 2026), effective July 2026 · source
For Zepbound and sleep apnea: "The patient has a diagnosis of moderate to severe obstructive sleep apnea", "The patient has a BMI ≥ 30 kg/m2" and "The patient has an apnea hypopnea index (AHI) ≥ 15 at baseline".
Blue Cross NC, Utilization Management Policy: Anti-Obesity Agents, NC Standard (July 2026), effective July 2026 · source
Policy history: "July 2026: Criteria change (Foundayo): Removed the step requirement from Foundayo." and "April 2026: Criteria update: Added new to market Foundayo and Wegovy HD to policy."
Blue Cross NC, Utilization Management Policy: Anti-Obesity Agents, NC Standard (July 2026), effective July 2026 · source
Its pharmacy utilization rules "apply to all commercial members with pharmacy benefit coverage through Blue Cross NC" and do not affect "any self-funded employer groups that carve out pharmacy benefits to another pharmacy benefits manager (PBM)."
Blue Cross NC, provider news: pharmacy utilization management 60-day network notice (effective October 1, 2026), effective October 2026 · source
What these documents cannot tell you
Everything above is what Blue Cross and Blue Shield of North Carolina publishes. None of it establishes what your own plan does, and the gap between those two things is wider than a carrier policy makes it look.
- Whether your plan includes anti-obesity medication coverage isn't in the policy. Your benefit booklet or HR can tell you.
- A self-funded employer that carves its pharmacy benefit out to another PBM isn't bound by this policy.
- The policy doesn't say which Blue Cross NC formularies list each drug.
- None of this is legal or medical advice. Your plan documents and your notice govern your case.
Where this comes from
- Blue Cross NC, Utilization Management Policy: Anti-Obesity Agents, NC Standard (July 2026), effective July 2026 — Open the document
- Blue Cross NC, provider news: pharmacy utilization management 60-day network notice (effective October 1, 2026), effective October 2026 — Open the document
Where to go next
- North Carolina Medicaid, and the state employee plan
- How employer and commercial plans treat GLP-1s
- Will insurance cover Zepbound for sleep apnea?
- How to appeal a commercial or employer plan denial
- Every carrier we have read
American GLP is not a law firm, an insurer, a government office or a clinician, and nothing here is legal or medical advice. This page describes what Blue Cross and Blue Shield of North Carolina publishes. It is not affiliated with Blue Cross and Blue Shield of North Carolina, and your own plan documents and your own notice govern your case. Policies carry effective dates and change — read the sources before you act.